Compounds > d-apv
Page last updated: 2024-12-08

d-apv

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID135342
CHEMBL ID84612
SCHEMBL ID158653
MeSH IDM0024151

Synonyms (61)

Synonym
CHEMBL84612
d-apv
PDSP1_000129
NCGC00024470-01
NCGC00015065-01
lopac-a-5282
tocris-0106
tocris-0105
NCGC00024471-01
PDSP2_000128
d(-)-2-amino-5-phosphonopentanoic acid, nmda receptor antagonist
d-(-)-2-amino-5-phosphonopentanoic acid
d-ap5
d-norvaline, 5-phosphono-
5-phosphono-d-norvaline
d-2-amino-5-phosphopentanoic acid
(r)-2-amino-5-phosphonopentanoic acid ,
79055-68-8
(2r)-2-amino-5-phosphonopentanoic acid
cas_79055-68-8
cb3371309
bdbm81977
HMS3261C18
AKOS006274118
NCGC00015065-02
d(-)-2-amino-5-phosphonovaleric acid (d-ap5)
d(-)-2-amino-5-phosphonopentanoic acid
LP00418
d-2-amino-5-phosphonovaleric acid
CCG-221722
2jj ,
SCHEMBL158653
tox21_500418
NCGC00261103-01
(2r)-amino-5-phosphonovaleric acid
d-2-amino-5-phosphonovalerate
HB0225
mfcd00078839
(r)-(-)-2-amino-5-phosphonopentanoic acid
sr-01000597642
SR-01000597642-3
VOROEQBFPPIACJ-SCSAIBSYSA-N
d-(-)-2-amino-5-phosphonopentanoic acid - cas 79055-68-8
BD162474
Q209309
HY-100714A
CS-0020421
SDCCGSBI-0633711.P001
NCGC00024471-03
(2r)-2-amino-5-phosphonopentanoic acid.
D92988
d-apv;d-2-amino-5-phosphonovaleric acid
DTXSID201000239
d-2-amino-5-phosphonovaleric acidd-apv
d-2-amino-5-phosphonopentanoic acid
EX-A6457
2-amino-5-phosphonovalerate, (r)-
(r)-ap-5
(-)-2-amino-5-phosphonopentanoic acid
CD39X2NL7F
2-amino-5-phosphonopentanoic acid, (r)-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency24.36160.177814.390939.8107AID2147
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID504865
NFKB1 protein, partialHomo sapiens (human)Potency5.01190.02827.055915.8489AID895; AID928
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency25.49050.001530.607315,848.9004AID1224819; AID1224820
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency22.38720.00106.000935.4813AID944
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)0.88000.00071.600310.0000AID144763
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Ki4.63860.00030.86666.6900AID1472311; AID1472312; AID1472313; AID1472314; AID239664; AID239665; AID239666
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)0.88000.00071.630610.0000AID144763
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Ki0.33500.00030.68056.6900AID1472311; AID239664
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)0.88000.00061.525710.0000AID144763
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Ki1.63000.00030.70716.6900AID1472312; AID239665
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)0.88000.00071.747210.0000AID144763
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Ki3.77000.00030.81966.6900AID1472313; AID239666
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)0.88000.00071.741110.0000AID144763
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Ki21.00000.00030.70726.6900AID1472314
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)0.88000.00071.741110.0000AID144763
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)0.88000.00071.741110.0000AID144763
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID239721Inhibitory constant against (S)-glutamate and glycine evoked currents mediated by N-methyl-D-aspartate glutamate receptor NR1a/NR2B expressed in Xenopus oocytes compared to NR1a/NR2C2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists.
AID146058Effective concentration against NR1/NR2A receptor2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID239722Inhibitory constant against (S)-glutamate and glycine evoked currents mediated by N-methyl-D-aspartate glutamate receptor NR1a/NR2D expressed in Xenopus oocytes compared to NR1a/NR2C2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists.
AID239119Displacement of L-[3H]glutamate from N-methyl-D-aspartate glutamate receptor in rat brain synaptic membranes2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Analogues of the neuroprotective tripeptide Gly-Pro-Glu (GPE): synthesis and structure-activity relationships.
AID1472313Antagonist activity at recombinant rat GluN1a/GluN2C expressed in Xenopus laevis oocytes assessed as inhibition of glycine/glutamate-mediated current responses by two-electrode voltage clamp method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
AID1472323Antagonist activity at NMDA receptor in Nras driven p53 deficient mouse HCC cell membranes assessed as LPS-stimulated PGE2 levels at 10 uM after 24 hrs by LC-MS/MS method (Rvb = 162 +/- 7%)2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
AID146064Effective concentration against NR1/NR2D receptor2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID295004Displacement of [3H]AMPA from AMPA receptor in rat cortical membrane2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Synthesis and pharmacological evaluation of novel conformationally constrained homologues of glutamic acid.
AID146062Effective concentration against NR1/NR2C receptor2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID239664Inhibitory constant against (S)-glutamate and glycine evoked currents mediated by N-methyl-D-aspartate glutamate receptor NR1a/NR2A expressed in Xenopus oocytes2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists.
AID1472314Antagonist activity at recombinant rat GluN1a/GluN2D expressed in Xenopus laevis oocytes assessed as inhibition of glycine/glutamate-mediated current responses by two-electrode voltage clamp method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
AID1472350Antiproliferative activity against Nras driven p53 deficient mouse HCC cells assessed as cell viability at 100 uM after 72 hrs by resazurin assay relative to control2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
AID1472312Antagonist activity at recombinant rat GluN1a/GluN2B expressed in Xenopus laevis oocytes assessed as inhibition of glycine/glutamate-mediated current responses by two-electrode voltage clamp method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
AID1472349Antagonist activity at NMDA receptor in Nras driven p53 deficient mouse HCC cell membranes assessed as potentiation of 10 uM sorafenib-mediated antiproliferative activity by measuring cell viability at 100 uM after 72 hrs by resazurin assay (Rvb = 31 +/- 2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
AID709976Antagonist activity at NMDA receptor GluN2B subunit in FVB mouse CA1 pyramidal neurons assessed as decrease in EPSC amplitude at holding potential of -60 mV at 50 uM measured at 5 mins by patch clamp electrophysiological assay in presence of Mg2+ free ACS2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Synthesis and biological characterization of 3-substituted 1H-indoles as ligands of GluN2B-containing N-methyl-D-aspartate receptors. Part 2.
AID1472346Antagonist activity at NMDA receptor in Nras driven p53 deficient mouse HCC cell membranes assessed as potentiation of 1 uM sorafenib-mediated antiproliferative activity by measuring cell viability at 100 uM after 72 hrs by resazurin assay (Rvb = 88 +/- 32017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
AID239665Inhibitory constant against (S)-glutamate and glycine evoked currents mediated by N-methyl-D-aspartate glutamate receptor NR1a/NR2B expressed in Xenopus oocytes2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists.
AID1472333Antagonist activity at NMDA receptor in Nras driven p53 deficient mouse HCC cell membranes assessed as PGE2 levels at 10 uM after 24 hrs by LC-MS/MS method relative to control2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
AID295005Displacement of [3H]KA from KA receptor in rat cortical membrane2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Synthesis and pharmacological evaluation of novel conformationally constrained homologues of glutamic acid.
AID1472348Antagonist activity at NMDA receptor in Nras driven p53 deficient mouse HCC cell membranes assessed as potentiation of 5 uM sorafenib-mediated antiproliferative activity by measuring cell viability at 100 uM after 72 hrs by resazurin assay (Rvb = 72 +/- 12017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
AID144763In vitro binding affinity for rat cortical membrane N-methyl-D-aspartate glutamate receptor determined using [3H]CPP as radioligand2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Synthesis and anticonvulsant activity of novel bicyclic acidic amino acids.
AID239667Inhibitory constant against (S)-glutamate and glycine evoked currents mediated by N-methyl-D-aspartate glutamate receptor NR1a/NR2D expressed in Xenopus oocytes2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists.
AID239720Inhibitory constant against (S)-glutamate and glycine evoked currents mediated by N-methyl-D-aspartate glutamate receptor NR1a/NR2A expressed in Xenopus oocytes compared to NR1a/NR2C2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists.
AID1472311Antagonist activity at recombinant rat GluN1a/GluN2A expressed in Xenopus laevis oocytes assessed as inhibition of glycine/glutamate-mediated current responses by two-electrode voltage clamp method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
AID1472332Antagonist activity at NMDA receptor in Nras driven p53 deficient mouse HCC cell membranes assessed as inhibition of NMDA-induced intracellular Ca2+ transients at 20 uM after 48 hrs by fluo-4AM dye-based fluorescence assay2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
AID239666Inhibitory constant against (S)-glutamate and glycine evoked currents mediated by N-methyl-D-aspartate glutamate receptor NR1a/NR2C expressed in Xenopus oocytes2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists.
AID1472347Antagonist activity at NMDA receptor in Nras driven p53 deficient mouse HCC cell membranes assessed as potentiation of 2.5 uM sorafenib-mediated antiproliferative activity by measuring cell viability at 100 uM after 72 hrs by resazurin assay (Rvb = 82 +/-2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
AID146060Effective concentration against NR1/NR2B receptor2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (35.71)29.6817
2010's5 (35.71)24.3611
2020's4 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.82 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.07 (4.65)
Search Engine Demand Index39.83 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glycine
[no description available]		3.110alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
2-amino-5-phosphonovalerate
2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.		2.0110non-proteinogenic alpha-amino acidNMDA receptor antagonist
alpha-methyl-4-carboxyphenylglycine
[no description available]		3.110
ibotenic acid
Ibotenic Acid: A neurotoxic isoxazole (similar to KAINIC ACID and MUSCIMOL) found in AMANITA mushrooms. It causes motor depression, ataxia, and changes in mood, perceptions and feelings, and is a potent excitatory amino acid agonist.		3.110non-proteinogenic alpha-amino acidneurotoxin
4-carboxy-3-hydroxyphenylglycine
4-carboxy-3-hydroxyphenylglycine: weak agonist at metabotropic glutamate receptors; occludes the action of 1-aminocyclopentyl-1,3-dicarboxylate in hippocampus		3.110hydroxybenzoic acid
phenytoin
[no description available]		2.0110imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
5,7-dichlorokynurenic acid
5,7-dichlorokynurenic acid: potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site		2.0110quinolines
1-aminoindan-1,5-dicarboxylic acid
1-aminoindan-1,5-dicarboxylic acid: structure given in first source		3.110
chlorpropham
Chlorpropham: A carbamate that is used as an herbicide and as a plant growth regulator.. chlorpropham : A carbamate ester that is the isopropyl ester of 3-chlorophenylcarbamic acid.		2.0110benzenes;
carbamate ester;
monochlorobenzenes		herbicide;
plant growth retardant
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		2.0110branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
felbamate
Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.		2.0110carbamate esteranticonvulsant;
neuroprotective agent
ifenprodil
ifenprodil: NMDA receptor antagonist		2.0710piperidines
n-methylaspartate
N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.		3.110amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		3.5120glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
quisqualic acid
Quisqualic Acid: An agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium mobilization from intracellular stores. The compound is obtained from the seeds and fruit of Quisqualis chinensis.		3.110non-proteinogenic alpha-amino acid
D-serine
[no description available]		3.110D-alpha-amino acid;
serine zwitterion;
serine		Escherichia coli metabolite;
human metabolite;
NMDA receptor agonist
L-2-aminoadipic acid
L-2-aminoadipic acid : The L-enantiomer of 2-aminoadipic acid.		3.1102-aminoadipic acidEscherichia coli metabolite;
human metabolite
1-amino-1,3-dicarboxycyclopentane
1-amino-1,3-dicarboxycyclopentane: RN given refers to (cis)-isomer		3.5120
2-amino-4-phosphonobutyric acid
(2S)-2-amino-4-phosphonobutanoic acid : A non-proteinogenc L-alpha-amino acid that is L-alpha-aminobutyric acid in which one of the hydrogens of the terminal methyl group has been replaced by a dihydroxy(oxido)-lambda(5)-phosphanyl group. It is a potent and selective agonist for the group III metabotropic glutamate receptors (mGluR4/6/7/8).		3.110non-proteinogenic L-alpha-amino acid;
phosphonic acids		metabotropic glutamate receptor agonist
eglumetad
eglumetad: LY-354740 is the active isomer, LY-366563 is the inactive isomer, and LY 314582 is the racemate; structure given in first source		3.110L-alpha-amino acid
3,5-dihydroxyphenylglycine
(S)-3,5-dihydroxyphenylglycine : A glycine derivative that is L-alpha-phenylglycine substituted at positions 3 and 5 on the phenyl ring by hydroxy groups.		3.110amino acid zwitterion;
non-proteinogenic L-alpha-amino acid;
resorcinols
d-ap7
[no description available]		2.0210
6-methyl-2-(phenylethynyl)pyridine
6-methyl-2-(phenylethynyl)pyridine: an mGlu5 antagonist. 2-methyl-6-(phenylethynyl)pyridine : A methylpyridine that coinsists of 2-methylp[yridine bearing an additional phenylethynyl group at position 6. Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw.		3.110acetylenic compound;
methylpyridines		anxiolytic drug;
metabotropic glutamate receptor antagonist
glycyl-prolyl-glutamic acid
glycyl-prolyl-glutamic acid: N-terminal cleavage product of IGF-1; has neuroprotective activity		2.0210oligopeptide
4-methylglutamic acid, threo-(l)-isomer
[no description available]		3.110
sib 1757
SIB 1757: a selective mGluR5 antagonist; structure in first source		3.110
l-2-(carboxypropyl)glycine
[no description available]		3.110
2r,4r-4-aminopyrrolidine-2,4-dicarboxylate
[no description available]		3.110pyrrolidinedicarboxylic acid
upf 596
UPF 596: structure in first source		3.110
sib 1893
SIB 1893: a selective mGluR5 antagonist; structure in first source		3.110
sdz eaa 494
midafotel : A member of the class of piperazines that is piperazine substituted by a carboxy group at position 2R and a (1E)-1-phosphonoprop-1-en-3-yl group at position 4. It is an antagonist of N-methyl-D-aspartate receptors (NMDARs) and was in clinical development by Novartis for the treatment of cognition disorders and brain injuries (now discontinued).		3.5120monocarboxylic acid;
olefinic compound;
phosphonic acids;
piperazinecarboxylic acid;
tertiary amino compound		anticonvulsant;
neuroprotective agent;
NMDA receptor antagonist
ro 25-6981
Ro 25-6981: blocks NMDA receptors containg NR2B subunit; structure in first source. Ro 25-6981 : A member of the class of piperidines that is 4-benzylpiperidine substituted by a 3-hydroxy-3-(4-hydroxyphenyl)-2-methylpropyl group at position 1 (the 1R,2S-stereoisomer). It is a potent antagonist of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor.		2.0710benzenes;
phenols;
piperidines;
secondary alcohol;
tertiary amino compound		anticonvulsant;
antidepressant;
neuroprotective agent;
NMDA receptor antagonist
ly 341495
[no description available]		3.110xanthenes
(1rs,1's)-peaqx
[no description available]		2.0210
ly 389795
LY 389795: a group II metabotropic glutamate receptor agonist; structure in first source		3.110
ly 379268
LY 379268: group II metabotropic glutamate receptor agonist; structure in first source. LY 379268 : An organic heterobicyclic compound that is (1R,5S)-2-oxabicyclo[3.1.0]hexane carrying amino, carboxy, and carboxy groups at positions 4R, 4R and 6R, respectively. It is a potent agonist of group II metabotropic glutamate receptors mGluR2 and mGluR3 (EC50 = 2.69 nM and 4.48 nM, respectively) that exhibits antipsychotic-like action in animal models of schizophrenia.		3.110amino dicarboxylic acid;
bridged compound;
organic heterobicyclic compound		antipsychotic agent;
anxiolytic drug;
metabotropic glutamate receptor agonist;
neuroprotective agent
nnz 2566
NNZ 2566: an (1-3) IGF-1 analog with neuroprotective activity		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110
Hepatocellular Carcinoma
[description not available]		02.1510
Cancer of Liver
[description not available]		02.1510
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.1510
Liver Neoplasms
Tumors or cancer of the LIVER.		02.1510
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510